Sjögren's Syndrome Management

Introduction to Management

The American College of Rheumatology recommends that treatment for Sjögren's syndrome should be tailored to specific symptoms and organ involvement, with topical therapies for sicca symptoms and systemic therapies reserved for patients with active systemic disease 1, 2

The European League Against Rheumatism (EULAR) suggests first-line therapy includes artificial tears containing methylcellulose or hyaluronate at least twice daily, with frequency increased as needed based on symptoms 1
Preservative-free formulations are recommended for patients requiring four or more applications per day, as suggested by the American Academy of Ophthalmology 1
Ophthalmic ointments can be used before bedtime to provide overnight symptom control, according to the American Academy of Ophthalmology 1
For refractory/severe ocular dryness, short-term (2-4 weeks) topical immunosuppressive therapy may be considered, as recommended by the European Society of Ophthalmology 1
Topical cyclosporine A is recommended for patients who don't respond to artificial tears, as suggested by the American College of Rheumatology 1, 2

The American Thoracic Society recommends that for patients with bronchiolitis, a trial of inhaled corticosteroids with or without macrolides is recommended 3
Patients with clinically relevant bronchiectasis should be treated with mucolytic agents/expectorants, nebulized saline or hypertonic saline, oscillatory positive expiratory pressure, postural drainage, mechanical high-frequency chest wall oscillation therapies, and chronic macrolides in those without non-tuberculous mycobacterium colonization, as recommended by the European Respiratory Society 3

The European League Against Rheumatism (EULAR) suggests that for fatigue and musculoskeletal pain, evaluate for contributing conditions and use analgesics according to pain severity following the WHO pain ladder 4
Hydroxychloroquine may be considered for fatigue and arthralgias, though evidence for efficacy is limited, as noted by the American College of Rheumatology 2
For chronic, non-inflammatory pain, physical activity and aerobic exercise are recommended rather than medications, as suggested by the European League Against Rheumatism (EULAR) 5

The European League Against Rheumatism (EULAR) recommends that systemic therapies should be restricted to patients with active systemic disease, and treatment should be tailored to organ-specific severity using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) definitions 5, 4
For moderate to severe systemic disease, glucocorticoids should be used at the minimum effective dose and duration, and immunosuppressive agents (azathioprine, mycophenolate, methotrexate) can be used as glucocorticoid-sparing agents, as recommended by the American College of Rheumatology 5, 4

Regular assessment of disease activity using validated tools such as the ESSDAI is recommended, as suggested by the European League Against Rheumatism (EULAR) 2, 6
For patients with pulmonary involvement, repeat pulmonary function tests every 6-12 months, as recommended by the American Thoracic Society 2
Monitor for development of lymphoma, which occurs in 2-5% of Sjögren's patients, as noted by the American College of Rheumatology 6

The European League Against Rheumatism does not list brimonidine as contraindicated or requiring special precautions in Sjögren's syndrome patients 7
Current guidelines suggest that brimonidine can be used in Sjögren's syndrome patients without exacerbating the autoimmune condition, according to the Annals of the Rheumatic Diseases 7